New Blockbuster Drugs Will More than Triple Acute Coronary Syndrome Treatment Market Value by 2023
GlobalData's report looks at the growth of monoclonal antibodies in the market for acute coronary syndrome treatment.
The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.
Across seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape, GlobalData said in a press release. Amgen’s evolocumab, Sanofi and Regeneron’s alirocumab, and Pfizer’s bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and GlobalData expects these treatments to be launched in the middle of the forecast period.
“These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment," said Eric J. Dimise, PhD, GlobalData’s analyst covering cardiovascular and metabolic disorders.
GlobalData has also identified two new anticoagulants, Janssen’s Xarelto and Merck’s Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years. “Xarelto is anticipated to achieve approval for the ACS indication in the US by 2018," says Dimise. "When added to the drug’s mounting sales in the EU, this will result in peak-year sales approaching $8 billion for ACS alone. Meanwhile, the PAR1 inhibitor, Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015."
“The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential,” concludes Dimise.
Source: GlobalData
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
